Abstract 3504
Background
Treatment selection requires review of patient (pt) and clinical features, medical literature, national guidelines, physician experience, and cost-value issues. The IBM Watson for Oncology with Cota RWE (WfO/Cota) point-of-care decision support tool ingests pt attributes from electronic health records and displays treatment recommendations (TRx) based on Memorial Sloan Kettering Cancer Center training and medical literature. The system has been recently supplemented with real world data curated by Cota listing historical treatments and survival outcomes drawn from the treating physician’s institution and a national database. WfO/Cota is undergoing testing at John Theurer Cancer Center (JTCC, Hackensack, NJ, USA). Concordance of WfO/Cota with expert opinions is required to confirm that cognitive computing TRx match best practices.
Methods
88 early stage post-menopausal breast cancer (BC) cases from the JTCC BC clinic were presented to 3 JTCC BC experts (without using WfO/Cota). The cases were compared against pts with similar demographic and disease characteristics from the Cota database (matched using Cota Nodal Address [CNA] algorithms).
Results
BC experts reviewed 223 cases (not all cases scored by each). WfO/Cota “recommended” option was concordant with selection by BC experts in 175 (78.5%) and “for consideration” option was selected in 21 (9.4%); experts agreed with WfO/Cota in 87.9%. 7 of 88 cases (8%) generated 59% of non-concordant responses with > =2 doctors disagreeing with WfO. The BC expert who worked at MSKCC deviated the least from MSKCC trained WfO. In the Cota database 69.3% of matched historical controls were treated with “recommended,” 11.4% “for consideration”, 19.3% “not recommended.”
Conclusions
WfO/Cota recommendations are largely concordant with disease expert best oncology practices. The observation that nearly a fifth of pts with similar disease (CNA) characteristics received non-recommended options in a real world database highlights a need. WfO/Cota is an innovative decision support tool that derives new insights based on existing real world evidence to reduce variations in practice.
Clinical trial identification
Legal entity responsible for the study
Cota.
Funding
IBM, Cota.
Editorial Acknowledgement
Disclosure
S.L. Goldberg: Cota: Employment, stock ownership. A.D. Norden, J. Hervey, C. Landstrom: Cota: Employment. A.L. Pecora: Cota: Stock ownership. J.L. Snowdon, P.M. Francis, N. Jungbluth, C.K. Wang, L. Latts: IBM: Employment. All other authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract